Opinion|Videos|September 13, 2024
CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you share your experience with CLL treatment? What factors were most important to you when making treatment decisions?
- How did your care team ensure you were educated about treatment options when it came to selecting treatment?
- How do you approach discussing potential adverse events with patients starting on treatments like? What strategies do you recommend for patients to effectively communicate any side adverse effects or concerns to their care team during treatment?
Advertisement
Related to this article
A review of 29 studies in more than 22,000 women 65 and older with ER-positive breast cancer found no statistically significant survival difference between hormone therapy alone and surgery first, though surgery controlled the cancer in the breast better.
The FDA approved Imfinzi plus Padcev before and after surgery for adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin.
Anxiety before a scan and while waiting for results is common for people with cancer and survivors. These five steps, drawn from ASCO, the American Cancer Society and the National Cancer Institute, can make the wait easier.
For Lung Cancer Awareness Month, five numbers from federal and American Cancer Society data show how survival for people with lung cancer has changed, how it differs by stage and type, and how many people are living with the disease.
A 12-year breast cancer survivor with 16 tattoos, including radiation marks, weighs new research on tattoos and lymphoma risk and the questions it prompts.
An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.
Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.
An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.
Advertisement
Advertisement
Trending on CURE
1
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
2
FDA Approves Imfinzi Plus Padcev for Some With Muscle-Invasive Bladder Cancer
3
5 Lung Cancer Survival Numbers Patients Should Know in 2026
4
Tattoos and Lymphoma Risk: A Breast Cancer Survivor's Questions
5